A5074872795- Cardiac Structural Anomalies and Repair
- Cardiac tumors and thrombi
- Mechanical Circulatory Support Devices
- Cardiac Valve Diseases and Treatments
- Transplantation: Methods and Outcomes
- Sarcoma Diagnosis and Treatment
- Cardiac pacing and defibrillation studies
- Aortic Disease and Treatment Approaches
- Vascular Tumors and Angiosarcomas
- Cardiac and Coronary Surgery Techniques
- Cardiac, Anesthesia and Surgical Outcomes
- Infective Endocarditis Diagnosis and Management
- Cardiac Ischemia and Reperfusion
- Cardiac electrophysiology and arrhythmias
- Cardiac Arrest and Resuscitation
- Pericarditis and Cardiac Tamponade
- Peptidase Inhibition and Analysis
- Atrial Fibrillation Management and Outcomes
- Cardiovascular Function and Risk Factors
- Electrospun Nanofibers in Biomedical Applications
- Tissue Engineering and Regenerative Medicine
- Cardiac Arrhythmias and Treatments
- ECG Monitoring and Analysis
- Cardiovascular Issues in Pregnancy
- Renal Transplantation Outcomes and Treatments
GTx (United States)
2025
Toronto General Hospital
2016-2025
University of Toronto
2016-2025
University Health Network
2015-2024
Princess Margaret Cancer Centre
2021
St. Michael's Hospital
1988-2021
University of Calgary
2021
Toronto Public Health
2011-2020
Ted Rogers Centre for Heart Research
2017
Electrophysiology and Heart Modeling Institute
2015
The HeartWare ventricular assist device (HVAD) is a new generation centrifugal flow VAD recently introduced in Canada. objective of this study was to compare the HVAD HeartMate II (HMII) axial device. Very few studies have compared clinical outcomes between newer VADs.All perioperative and follow-up data on LVAD recipients were collected prospectively our institutional database. Between January 2006 April 2012, 46 consecutive patients underwent implantation either an (n=13) or HMII (n=33)...
Intimal (spindle cell) sarcomas of the left atrium are extremely rare primary cardiac tumours with three cases reported (Li et al. (2013), Cho (2006), and Modi (2009)). We present a 69-year-old man who first came to medical attention after experiencing abdominal discomfort. He had 30 lb weight loss apparently due dieting. denied any other constitutional symptoms. His symptoms persisted despite course antibiotics for presumed diverticulitis. Laboratory values were within normal limits, though...
Abstract Background Primary cardiac sarcoma (PCS) is a rare but often fatal disease. The current study aimed to analyze the impact of baseline demographics, local and systemic therapies in contemporary cohort. Methods Clinical records PCS across six institutions three continents were reviewed. Kaplan‐Meier method was used estimate survival. Cox proportional hazard model determine variables impacting progression‐free survival (PFS) or overall (OS). Results Sixty‐one patients with (1996‐2016)...
Objective Pericardial patches for intraventricular repair are limited by progressive calcification, thickening, and retraction. The aim of this study was to evaluate the safety CorMatrix extracellular matrix (ECM) mechanical complications myocardial infarction (MI). Methods ECM is a novel material synthesized from decellularized porcine small intestinal submucosa. Between July 2011 October 2012, total 11 consecutive patients with post-MI including ventricular aneurysm (n = 7), septal defect...
The natural history of cardiac tumors is dismal, with death ensuing rapidly. This especially true incomplete resection (called R-2 resection). We present a patient metastatic sarcoma, also involving the heart, too unwell to undergo chemotherapy, who underwent debulking operation, resulting in early rapid recurrence but response from chemotherapy. Debulking may be selectively offered enable chemotherapy initiation.
Abstract Introduction: The use of mechanical circulatory support (MCS) in nontransplant eligible candidates remains controversial. Our decision to offer MCS for has led their reevaluation after a period left ventricular assist device (LVAD) support. Methods: From 2001 September 2009, we had 37 patients who received an implantable LVAD, 22 (59%) were not deemed be transplant at the time LVAD insertion (bridge candidacy, BTC group). Results: Fifteen (41%) considered transplant, BTT group) and...